Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

to Evaluate the Safety and Efficacy of LY011 Cell Injection（Targeting CLDN 18.2 Chimeric Antigen Receptor T Cells） in the Treatment of Advanced Gastric Adenocarcinoma

NCT04977193 is registered in ClinicalTrials.gov with Shanghai Longyao Biotechnology Inc., Ltd. as lead sponsor.

NCT NCT04977193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04977193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
to Evaluate the Safety and Efficacy of LY011 Cell Injection（Targeting CLDN 18.2 Chimeric Antigen Receptor T Cells） in the Treatment of Advanced Gastric Adenocarcinoma
Lead sponsor
Shanghai Longyao Biotechnology Inc., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
November 1, 2021
Completion date
November 1, 2024
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric adenocarcinoma